Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tissue action plan

This article was originally published in The Gray Sheet

Executive Summary

FDA delays effective date to Jan. 21, 2004 for registration and listing of establishments engaging in the processing of all human cells, tissues and cellular and tissue-based products (HCT/Ps) not currently regulated. In a Federal Register notice slated for publication Jan. 21, FDA cites "numerous comments submitted" to the agency, concluding "that implementing the registration final rule under the staggered effective date for remaining HCT/Ps would be contrary to the public interest." CBER recently explained that the agency first intended to publish a donor suitability final rule before concurrently implementing it with GTP final rules (1"The Gray Sheet" Oct. 21, 2002, p. 26). FDA will continue to accept voluntary registrations...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017776

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel